Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Fortrea Holdings Inc.

Healthcare US FTRE

15.63USD
0.27(1.76%)

Last update at 2026-06-03T20:00:00Z

Day Range

14.4715.65
LowHigh

52 Week Range

3.9718.67
LowHigh

Fundamentals

  • Previous Close 15.36
  • Market Cap964.92M
  • Volume1021534
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA41.50M
  • Revenue TTM2723.40M
  • Revenue Per Share TTM29.86
  • Gross Profit TTM 503.80M
  • Diluted EPS TTM-10.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -983.00000M -275.00000M -30.50000M 58.90M 136.40M
Minority interest - - - - -
Net income -986.20000M -328.50000M -25.20000M 58.40M 98.00M
Selling general administrative 456.40M 560.70M 336.60M 299.90M 303.10M
Selling and marketing expenses - - - - -
Gross profit 425.80M 534.20M 590.60M 621.70M 604.40M
Reconciled depreciation 78.00M 86.90M 96.40M 92.70M 166.30M
Ebit -891.60000M -151.20000M 39.20M 236.10M 135.50M
Ebitda -813.60000M -64.30000M 137.20M 328.80M 301.80M
Depreciation and amortization 78.00M 86.90M 98.00M 92.70M 166.30M
Non operating income net other - - - - -
Operating income -30.60000M -161.90000M 32.00M 185.20M 114.30M
Other operating expenses 2754.00M 2858.30M 2810.50M 2870.60M 2922.50M
Interest expense 91.40M 123.80M 69.80M 132.40M -
Tax provision 3.20M -3.50000M 4.50M 0.50M 38.40M
Interest income - - - - -
Net interest income -91.40000M -123.80000M -69.80000M -132.40000M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.20M -3.50000M 1.20M 0.50M 38.40M
Total revenue 2723.40M 2696.40M 2842.50M 3096.10M 3057.50M
Total operating expenses 456.40M 696.10M 558.60M 396.20M 469.40M
Cost of revenue 2297.60M 2162.20M 2251.90M 2474.40M 2453.10M
Total other income expense net -952.40000M -113.10000M -62.50000M -34.20000M 1.40M
Discontinued operations - - - - -
Net income from continuing ops -986.20000M -271.50000M -3.40000M 58.40M 98.00M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2715.70M 3579.20M 4357.20M 4287.90M 4368.70M
Intangible assets 622.00M 655.70M 771.20M 823.30M 935.50M
Earning assets - - - - -
Other current assets 132.90M 135.70M 35.10M 83.50M 73.10M
Total liab 2152.20M 2216.80M 2618.40M 945.30M 1108.10M
Total stockholder equity 563.50M 1362.40M 1738.80M 3342.60M 3260.60M
Deferred long term liab - - - - -
Other current liab 395.80M 317.10M 356.10M 322.70M 435.20M
Common stock 0.10M 0.10M 0.10M - -
Capital stock 0.10M 0.10M 0.10M - -
Retained earnings -1383.20000M -397.00000M -49.10000M - -
Other liab - - - - -
Good will 960.00M 1710.40M 2029.30M 1997.30M 2080.90M
Other assets - - - - -
Cash 174.60M 118.50M 108.60M 112.00M 94.60M
Cash and equivalents - - - - -
Total current liabilities 913.30M 949.50M 775.90M 699.00M 826.70M
Current deferred revenue 473.80M 353.30M 241.40M 271.50M 307.00M
Net debt -106.60000M 1080.00M 1569.40M -48.60000M -17.40000M
Short term debt 14.00M 88.20M 45.60M 23.30M 24.00M
Short long term debt 4.80M 74.80M 26.10M - -
Short long term debt total 68.00M 1198.50M 1678.00M 63.40M 77.20M
Other stockholder equity 2116.60M 2042.20M 2006.20M 3618.60M 3409.00M
Property plant equipment - - - - -
Total current assets 897.20M 948.20M 1253.10M 1246.90M 1117.50M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 589.70M 694.00M 1074.10M 1051.40M 949.80M
Long term debt 1048.00M 1049.70M 1565.90M - -
Inventory - - 35.30M - -
Accounts payable 29.70M 138.20M 132.80M 81.50M 60.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -170.00000M -282.90000M -218.40000M -276.00000M -148.40000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 80.80M 103.40M 79.50M 54.30M 70.80M
Deferred long term asset charges - - - - -
Non current assets total 1818.50M 2631.00M 3104.10M 3041.00M 3251.20M
Capital lease obligations 63.20M 74.00M 86.00M 63.40M 77.20M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 251.60M -31.80000M -54.00000M -26.20000M
Change to liabilities - - - - -
Total cashflows from investing activities 14.40M 251.60M -31.80000M - -
Net borrowings -75.70000M -482.70000M 1616.00M - -
Total cash from financing activities -76.30000M -497.80000M -140.80000M -8.70000M -128.50000M
Change to operating activities - - - - -
Net income -986.20000M -271.50000M -25.20000M 192.90M 98.00M
Change in cash 56.10M 9.90M -1.80000M 17.40M 14.30M
Begin period cash flow 118.50M 108.60M 110.40M 94.60M 80.30M
End period cash flow 174.60M 118.50M 108.60M 112.00M 94.60M
Total cash from operating activities 113.50M 262.80M 168.40M 87.50M 169.80M
Issuance of capital stock - - - - -
Depreciation 78.00M 98.00M 98.00M 92.70M 166.30M
Other cashflows from investing activities 39.60M 0.50M 8.50M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 70.90M 309.90M -53.40000M - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -76.30000M -15.10000M -1756.80000M -8.70000M -128.50000M
Change to netincome - - - - -
Capital expenditures 25.20M 25.50M 40.30M 54.40M 26.50M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 114.70M 364.50M 26.90M -245.80000M -127.20000M
Stock based compensation 74.40M 58.40M 42.70M 25.40M 27.50M
Other non cash items 864.60M 38.00M 67.60M 38.80M 35.40M
Free cash flow 88.30M 237.30M 128.10M 33.10M 143.30M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FTRE
Fortrea Holdings Inc.		 0.27 1.76% 15.63 - 6.00 0.35 1.71 0.70 92.35
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Fortrea Holdings Inc.

8 Moore Drive, Durham, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Thomas H. Pike CEO, President & Chairman 1959
Ms. Jill McConnell Chief Financial Officer 1975
Mr. Mark A. Morais COO & President of Clinical Services 1977
Amanda M. Warren Chief Accounting Officer NA
Ms. Hima B. Inguva Head of Investor Relations & Corporate Development NA
Stillman Hanson General Counsel & Corporate Secretary NA
Dr. John J. Doyle President of Consulting NA
Mr. Anshul Thakral CEO & Director 1978
Mr. Drayton Virkler President & Chief Commercial Officer NA
Mr. Robert Parks Chief Accounting Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.